SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Sol-Gel Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

Pivotal Phase 3 trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome reached last patient last v

SLGL

Related stories